ABI ambri limited

ambri - one to watch

  1. 723 Posts.
    lightbulb Created with Sketch. 129
    Ambri have confirmed that they are in the final stages of optimising the design and manufacturing method of the disposable cartridge component of their SensiDx unit (nanotechnology point-of-care blood testing product). Problems with high volume manufacturing of the disposable cartridge had caused a delay in the release of the product. If the company can be taken at its word, we should see a 2-3 week shake down period begin soon. This will be followed by 3-4 months of clinical trials. My guess is that ABI will be seeking FDA approval by about June or July 03. The company will be releasing a milestone statement in mid to late Feb.
    In addition to the SensiDx product, ABI are doing research for the US department of defence on a diagnostic tool for testing chemical and biological warefare agents. ABI are also conducting revenue-generating research for Dow Corning, Genencore, and Proctor and Gamble.
    ABI also have plenty of cash on hand ($13m). Cash outflow for the present quarter is expected to be only around $3m. The $6.8m outflow for the Dec quater was a one off (see company statements).
    Thorney hold 5.68% of the stock. Dow Corning and Genencor hold roughly 7%.
watchlist Created with Sketch. Add ABI (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.